

SUNDAY, MAY 24, 2015 PRECONFERENCE WORKSHOPS			
	Workshop 1 [Half Day]	Workshop 2 [Full Day]	Workshop 3 [Full Day]
08:30 -12:00		Non-CRF Data (eData) is Equivalent Important as CRF Data in Clinical Trials	How to Complete a CDISC-Compliant CRF Annotation
13:30 - 17:30	Essential Biostatistics Concepts Made Easy		
MONDAY, MAY 25, 2015 CONFERENCE DAY 1			
13:30 - 17:30	Opening Plenary Session + Special Forum		
17:30 - 19:00	Networking Reception		
TUESDAY, MAY 26, 2015 CONFERENCE DAY 2			
	Theme 1	Theme 2 / Theme 12	Theme 3
	Understanding China Regulatory Landscape	Theme 2: CFDA Town Hall Theme 12: Hot Topics and Late Breaker	Clinical Science and Clinical Trial Operation
Session 1 08:30 - 10:00	Session 0101 Successful Stories of Bringing Innovative Product into China Market	Session 1201 How to Create Efficient Communications for Stakeholders of Drug R&D Chain	Session 0301 The Responsibilities to Speed Up Clinical Trials
10:00 - 10:30	TEA BREAK		
Session 2 10:30 - 12:00	Session 0102 ICH E17 MRCT Guidance Development Update	Session 1202 Expedited Development, Access and Approval Pathways	Session 0302 The Feasibilty of Initiating Clinical Trials by Single IRB Approving in China
12:00 - 13:30	LUNCH		
Session 3 13:30 - 15:00	Session 0203 China Food and Drug Administration (CFDA) Town Hall (Part I)		
15:00 - 15:30	TEA BREAK		
Session 4 15:30 - 17:30	Session 0204 China Food and Drug Administration (CFDA) Town Hall (Part II)		
WEDNESDAY, MAY 27, 2015 CONFERENCE DAY 3			
	Theme 1	Theme 12	Theme 3
	Understanding China Regulatory Landscape	Hot Topics and Late Breaker	Clinical Science and Clinical Trial Operation
Session 5 08:30 - 10:00	Session 0105 How Transparency Evolve in Key Authority and How It Help Industry R&D Capability Build Up	Session 1205 Medical Affairs - How to Deliver the Latest Medical Knowledge to the Health Professional	Session 0305 Cinical Science (Part I) - Development Strategy
10:00 - 10:30	TEA BREAK / ANNOUNCEMENT OF POSTER PRIZE WINNERS		
Session 6 10:30 - 12:00	Session 0106 How Multiple-Disciplinary Department in Authority Works Together Collaboratively to Manage/Regulate Product Quality	Session 1206 On the Way - China Innovative Pharmaceutical Company	Session 0306 Clinical Operation - Risk Based Monitoring
12:00 - 13:30	LUNCH		
Session 7 13:30 - 15:00	Session 0107 How Far Away is the Innovative Medicine to China Patients	Session 1207 Drug-Diagnostic Co-Development and Regulatory Requirement and Challenges for Companion Diagnostic Test	Session 0307 Cinical Science (Part II) - IMCT Latest Guidance Population PK Value in Development
15:00 - 15:30	TEA BREAK		
Session 8 15:30 - 17:30			Session 0308 Project Management - Study Wide

SUNDAY, MAY 24, 2015 PRECONFERENCE WORKSHOPS			
Workshop 4 [Full Day]	Workshop 5 [Half Day]		
Exploring Medical Communications Services to Support Patient Care Decisions	Lean: Innovative Approaches for Authoring Clinical Regulatory Documents		

THE 7TH DIA CHINA ANNUAL MEETING AT-A-GLANCE


TUESDAY, MAY 26, 2015 CONFERENCE DAY 2			
Theme 4	Theme 5	Theme 6	Theme 7
Quantitative Science	Risk Assessment, Management & Communication	CMC and Quality System	Biologic Development
Session 0401 Oncology Statistics	Session 0501 Patient Safety in First-In-Human Clinical Trial	Session 0601 Managing Post-Approval CMC Changes in a Global Market	Session 0701 New Trend/Technology in Biologic Development
TEA BREAK			
Session 0402 Application of Bayesian Methods for Clinical Trials	Session 0502 Clinical Development - Benefit and Risk Based Decision	Session 0602 CHP Townhall	Session 0702 Safety Evaluation of New Types of Antibodies
LUNCH			
	Session 0503 Post Marketing Safety Surveillance	Session 0603 Multiple Sites for Biologicals in China	Session 0703 Development of Biosimilars in China (Part I): Interpretation of Biosimilar Guidance
TEA BREAK			
	Session 0504 Effective Risk Management	Session 0604 Effective Management of Contract Manufacturing Organization	Session 0704 Development of Biosimilars in China (Part II): Opportunities and Challenges

WEDNESDAY, MAY 27, 2015 CONFERENCE DAY 3			
Theme 4	Theme 5		Theme 7
Quantitative Science	Risk Assessment, Management & Communication		Biologic Development
Session 0405 Involving CDM Role	Session 0505 Vaccine Safety		Session 0705 Detection and Evaluation of Immunogenicity of Biologics
TEA BREAK / ANNOUNCEMENT OF POSTER PRIZE WINNERS			
Session 0406 Quality and Integrity of Clinical Trial Data	Session 0506 Herbs Safety		
LUNCH			
Session 0407 Stat/DM Joint Session - The Collaboration of DM and Statistics (Part I)			
TEA BREAK			
Session 0408 Stat/DM Joint Session - The Collaboration of DM and Statistics (Part II)			

QUICK GUIDE:

● Theme Line

● Date/Time Line




STAY UP TO DATE WITH DIA!


Weibo

WeChat

DIA China Home Page







DIA

DEVELOP
INNOVATE
ADVANCE

TUESDAY, MAY 26, 2015 CONFERENCE DAY 2			
Theme 8	Theme 9	Theme 10	Theme 11
Therapeutically Specific Issues in Drug Development	Functional Specific Issues in Durg Development	China and Beyond - WHO PQ, Generic Drug and Botanic Drug Pathway	Innovative Partnership and Business Model for Drug Development in China Beyond
Session 0801 Global Landscape of Innovative Clinical Development	Session 0901 Medical Writing Evolution and Expansion: from Global to China, from the Past to the Future	Session 1001 WHO Vaccine (Part I): Global Regulatory and Procurement Requirements	
TEA BREAK			
Session 0802 Opportunities & Transformation of TA Related Clinical Development in China	Session 0902 Embrace the Dynamic Environmental Change: Innovations Lead to New Opportunities and Solutions	Session 1002 WHO Vaccine (Part II): Newer than New-Innovations to Create New Health Solutions	
LUNCH			
Session 0803 High and Lows in Diabetes	Session 0903 Why is Professional Medical Writer Needed in Boosting Scientific Publication in China	Session 1003 Botanical (Part I): Developing New Drugs from Traditional Chinese Medicine for Unmet Public Health Needs	Session 1103 Partnership Strategies and Creative Frameworks in the New Era
TEA BREAK			
	Session 0904 Regulatory Writing: CTD, ICH E3 - Compliant CSR, and China Submission Dossier Preparation (Clinical Parts)	Session 1004 Botanical (Part II): Developing New Drugs from Traditional Chinese Medicine for Unmet Public Health Needs	Session 1104 Money, Technology and Legal Structure - Put Together the Jigsaw Puzzle for an Innovative Partnership
WEDNESDAY, MAY 27, 2015 CONFERENCE DAY 3			
Theme 8	Theme 9	Theme 10	Theme 11
Therapeutically Specific Issues in Drug Development	Functional Specific Issues in Durg Development	China and Beyond - WHO PQ, Generic Drug and Botanic Drug Pathway	Innovative Partnership and Business Model for Drug Development in China Beyond
Session 0805 Clinical Development (Part I) - The Critical Successful Factor for New Drug Development	Session 0905 Technology Leads to New Opportunities for Meeting Customer Medical Information Needs	Session 1005 Generic Drug Forum (Part I) - Global Requirements and Regulatory Initiatives	
TEA BREAK / ANNOUNCEMENT OF POSTER PRIZE WINNERS			
Session 0806 Clinical Development (Part II) - What Are the Gaps & Opportunities for China	Session 0906 Innovative Approaches to Ensuring Quality in Clinical Trials and Compliance to GCP	Session 1006 Generic Drug Forum (Part II) - Product Development for Quality Consistency	
LUNCH			
	Session 0907 Internationalization of Chinese CRO	Session 1007 Generic Drug Forum (Part III) - Lessons Learned from Quality and Compliance Inspections	Session 1107 Regulatory Aspect of the Innovative Partnership (Part I)
TEA BREAK			
	Session 0908 Site & SMO		Session 1108 Regulatory Aspect of the Innovative Partnership (Part II)